Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms
暂无分享,去创建一个
E. Estey | F. Appelbaum | M. Othus | R. Walter | H. Erba | P. Becker | P. Hendrie | B. Scott | M. Percival | K. Gardner | S. Buckley | A. Halpern | Tara L. Chen | E. Huebner | K. F. Orlowski | A. Anwar | Emily M. Huebner | Kaysey F. Orlowski | Kelda M. Gardner
[1] C. Bloomfield,et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.
[2] Yunsuk Choi,et al. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Gale,et al. Gemtuzumab ozogamicin in acute myeloid leukemia , 2017, Leukemia.
[4] C. Hourigan,et al. Measurable residual disease testing in acute myeloid leukaemia , 2017, Leukemia.
[5] E. Vellenga,et al. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. , 2017, Blood.
[6] G. Lyman,et al. Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit , 2017, JAMA oncology.
[7] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[8] E. Estey,et al. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[10] E. Estey,et al. Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia , 2016, Leukemia.
[11] E. Estey,et al. Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia , 2016, Leukemia.
[12] W. Jędrzejczak,et al. Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. , 2016, Blood.
[13] C. Clarke,et al. Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis , 2015, Cancer.
[14] J. Lancet,et al. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. , 2014, Leukemia research.
[15] E. Estey,et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson , 2014, Leukemia.
[16] Lars Kjeldsen,et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] H. Kantarjian,et al. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. , 2013, Clinical lymphoma, myeloma & leukemia.
[18] R. Larson,et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.
[19] F. Ferrara,et al. Acute myeloid leukaemia in adults , 2013, The Lancet.
[20] W. Jędrzejczak,et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] E. Estey,et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Daohai Yu,et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome , 2011, Cancer.
[23] E. Estey,et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Lancet,et al. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. , 2011, Leukemia research.
[25] R. Hills,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.
[26] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[27] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[28] E. Estey,et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. , 2007, Blood.
[29] T. Robak,et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G‐CSF (CLAG‐M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group , 2007, European journal of haematology.
[30] W. Jędrzejczak,et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study , 2004, Leukemia.
[31] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[33] J. Yates,et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. , 1973, Cancer chemotherapy reports.
[34] M. Patnaik,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[35] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.